Selank has a well-defined heptapeptide sequence and there is an existing body of experimental research looking at various aspects of its molecular biology. By contrast, Adamax poses a different research issue; although the name is found in commercial and secondary research sources, it is difficult to establish a clearly developed body of peer-reviewed literature concerning a compound specifically identified as Adamax. Some of the more recent sources refer to it as a modified Semax-related peptide, while others give inconsistent accounts of its identity. The fact that they are in the same neuropeptide category should not lead to automatically assigning research findings from Selank or Semax to Adamax.
Why Compound Identity Matters in Peptide Research
Just having a peptide name is not enough to determine molecular identity.
In laboratory research it is important to associate the identity of a peptide with measurable properties such as its amino acid sequence, molecular mass, any chemical modifications and analytical data; this is especially so when there is a limited amount of primary literature on a compound or when it is listed under several different descriptions.
Selank is an example of a research substance for which a relatively clear definition exists. According to PubChem Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro and this sequence is also mentioned in published studies.
It is harder to assess Adamax on the basis of the original literature; the existing secondary sources refer to it either as a modified Semax-related compound, as a combination involving N-acetylated Semax and Selank, or as another modified peptide structure. These descriptions on their own are not enough to confirm a single widely accepted chemical identity.
That is why researchers ought to treat a supplier's product name as different from the chemically verified compound identity.
Selank Has a Defined Peptide Sequence
Selank is a synthetic peptide consisting of seven amino acids, specifically threonine, lysine, proline, arginine, proline, glycine, and proline.
His published research has involved studies on neuropeptide biology, enkephalin metabolism and GABAergic signalling. In one study it was found that Selank prevented the enzymatic breakdown of plasma enkephalin in an experimental system, thus providing a biochemical basis for further investigation into its interaction with neuropeptide metabolism.
Other studies have looked into the changes in genes linked with GABAergic neurotransmission. In experiments carried out on the frontal cortex of rats, exposure to Selank caused a modification in the expression of a number of genes related to neurotransmission. The researchers suggested that interaction with the GABAergic system might be one element of its molecular activity, although the exact molecular mechanism is still an area under investigation.
What these findings show is that research into Selank is based on measurable biochemical and molecular endpoints rather than depending entirely on general descriptions of its biological effects.
Adamax and the Problem of Limited Primary Literature
With regard to Adamax, the scientific view is different.
A search of the biomedical literature fails to show that there is a substantial number of peer-reviewed studies which have been carried out specifically on a compound consistently known as Adamax. The sources that are oriented towards research themselves point out that the evidence relating to Adamax is either limited or not there at all, and the descriptions of its structure differ from one supplier to another.
This establishes a clear distinction between evidence specific to a compound and evidence relating to a related compound.
Research involving Semax could be of some use when looking into the proposed Semax-related structure; it does not nevertheless show that Adamax has the same molecular activity.
One can therefore not use research involving Selank to determine the properties of an Adamax material.
Since the material is experimental and has only been somewhat independently characterized, analytical verification is particularly important.
Adamax and Semax Should Not Be Treated as the Same Peptide
The secondary literature often links Adamax with Semax, but the two names should not be treated as equivalent.
The peptide identity of Semax is clearly documented. According to PubChem the sequence is Met-Glu-His-Phe-Pro-Gly-Pro and the peptide is identified as ACTH(4-7)-Pro-Gly-Pro.
The subject of Semax has been looked at in rodent models through peer-reviewed studies, these studies including those which examined the expression of BDNF and TrkB in the hippocampus as well as that of the BDNF and NGF genes in various areas of the brain.
The studies provide evidence concerning Semax.
Evidence regarding an independently defined Adamax material is only presented when the material being tested has the same verified molecular identity.
It is important to make this distinction when interpreting claims which are based on structural ancestry.
Structural Modification Can Change Experimental Behaviour
Small changes in structure can change how peptides act.
Altering the terminal groups, the amino acid sequence, the stereochemistry or any other chemical properties may have an effect on receptor interaction, proteolytic stability, molecular recognition and analytical behaviour.
The example of semax shows how a short peptide sequence can be examined using a number of molecular indicators, with studies having looked at specific binding in the basal forebrain tissue of rats and at changes in BDNF protein levels after experimental exposure.
A modified analogue should therefore be regarded as a different research material until its structure and biological properties have been determined.
This is particularly relevant to Adamax because secondary sources do not provide a consistent, independently established identity.
Selank Research and Enkephalinase Activity
A aspect of Selank research is the way in which endogenous enkephalins are metabolised.
Enkephalins are short endogenous opioid peptides which are susceptible to enzymatic degradation. A study that was published in 2001 looked at the effect of Selank on the plasma enzymes that degrade enkephalins and found that it inhibited the hydrolysis of enkephalins in a concentration-dependent manner.
It is useful to carry out this kind of study since the endpoint in question is biochemical and can be measured. Instead of depending only on observations of behaviour, the researchers are able to look directly at enzyme activity.
A biochemical observation must be kept apart from clinical interpretation since the fact that an enzyme is inhibited in an experimental system does not on its own mean that a therapeutic effect has been achieved.
Selank and GABAergic Research
A further area of research is concerned with GABAergic neurotransmission.
A study which looked at Selank in the frontal cortex of rats examined the expression of 84 genes concerned with neurotransmission, including those linked to GABA receptors, transporters, ion channels and other neurotransmitter systems; changes in gene expression were noted at various time points following experimental exposure.
Research into receptor binding has indicated that Selank may have an effect on binding to GABA receptors and has proposed that concentration-dependent allosteric modulation could be one possible mechanism. The authors stated this to be a molecular hypothesis, supported by their experimental results, rather than offering it as a certain explanation of all the peptide's biological actions.
When evaluating the literature concerning peptides it is necessary to tell the difference between an observed molecular interaction and a fully established mechanism.
Semax Research Provides Context, Not Proof for Adamax
Semax is useful as a reference point when people are talking about Adamax within the same field of research.
Several studies have looked at Semax in connection with neurotrophin signalling. One study on the rat hippocampus found changes relating to BDNF and TrkB, while in another the temporal changes in the expression of the BDNF and NGF genes after experimental exposure were investigated.
Research based on cells has likewise looked at the rapid induction of neurotrophin messenger RNA after exposure to Semax.
The studies show that Semax has an established body of experimental work involving molecular and transcriptomic endpoints.
One must not take this as proof that a material of the Adamax type has the same effect. Any proposed analogue has to be characterized and subjected to experimental validation of its own.
Comparing Research Questions Rather Than Claimed Effects
A comparison between Adamax and Selank that is to have scientific value should first focus on research identity rather than on the claimed results.
As for Selank, researchers can examine a particular heptapeptide sequence, as well as the interactions with enzymes, the mechanisms involving receptors, gene expression and the neurochemical endpoints. The literature which has already been published provides a number of possible starting points for experiments.
The first of Adamax's research questions is of a more fundamental nature: precisely what is the substance being investigated?
It means establishing the molecular identity before assigning the results from the related peptides to it.
What has to be investigated in the case of a substance being called a modified Semax analogue is whether the mass it exhibits, the sequence of its components, and the chemical modifications correspond to those of the proposed structure; otherwise the mechanistic conclusions remain uncertain.
Analytical Verification of Experimental Peptides
It is especially important to carry out an analytical characterization when looking at compounds about which there is a limited amount of published material.
Liquid chromatography can give details regarding chromatographic purity, and mass spectrometry can be used to determine molecular mass and identity. If the research question dictates it, other analytical techniques may be suitable for confirming sequence or structural modifications.
With a peptide that has been well characterised such as Selank, the analytical results can be compared with its established sequence and with the expected molecular properties.
For Adamax, analytical confirmation also has a role since the published literature does not contain a generally accepted identity of the compound. The analytical record must therefore be linked to the exact batch and to the chemical description given for the material.
Experimental Models Used in Selank Research
The research into selank has involved biochemical assays, experiments using cells and animal models.
Studies involving enzymes have looked at their interactions with enkephalin-degrading systems. Molecular studies have examined the expression of genes related to neurotransmission in tissue from the rat brain. Experiments on other animals have looked at neurochemical and behavioural endpoints.
They offer various kinds of evidence.
An enzyme assay can show biochemical activity. A cell model can study gene expression or receptor-related signalling. An animal model can look at integrated biological responses.
The findings should thus be understood in the light of the model rather than being merged into one general statement.
Experimental Models for Adamax Require Greater Identity Control
The amount of literature that is specific to Adamax has to be taken into account when carrying out an experimental interpretation.
In order for a biological experiment to identify a mechanism, researchers first have to know what material was actually used in the experiment. Since different suppliers may give the same name to materials that have different chemical compositions, the results obtained with one material cannot simply be attributed to another.
It therefore becomes especially important to carry out sequence confirmation, molecular-mass analysis, purity testing and keep detailed records of each batch.
That is to say that studies concerning Semax, Selank or other similar peptides should be cited as background evidence rather than treated as direct evidence for Adamax.
Evidence Limitations
The main limitation of this comparison is not the absence of interesting hypotheses but rather the difference in the quality of the evidence for the two compounds.
There is a clear sequence and a range of published experimental studies relating to several molecular pathways for Selank.
Evidence that is specific to Adamax is only moderately well established in the scientific literature available. The existing secondary sources give differing accounts of its structure and of its relationship to the other peptides.
As a result, any statements about Adamax should be divided into three types: those relating to the confirmed chemical identity, those based on evidence from related compounds, and the hypotheses which need to be validated by direct experimentation.
It is impossible to regard the results obtained with Semax or Selank as being confirmed results when it comes to Adamax.
What This Comparison Shows
From the point of view of research evidence, Adamax and Selank have different positions.
Selank has a clearly defined heptapeptide sequence and is the subject of a body of published work which includes studies at the biochemical, molecular, and animal levels.
Adamax is not as direct since the name goes with inconsistent descriptions and has a lack of independently verifiable primary research.
The main scientific distinction is therefore not about which peptide leads to a given result; it is instead whether the substance has a sufficiently well-established molecular identity and a solid evidence base to support a particular mechanistic conclusion.
For researchers, the distinction will decide if a published result can be applied directly, if it provides only indirect information or if it remains merely a hypothesis that needs further investigation.
Research Use Only
The information given on this page is for use in scientific and educational research only.
The peptides discussed here are not being offered as medicines, treatments, dietary supplements or products for human consumption and no information is given regarding dosing, administration or therapeutic advice.
When interpreting the published findings, due account must be taken of the experimental model, the identity of the compound, and the limitations of the study. Research materials should be assessed by means of the relevant analytical documentation and information specific to the batch.
Researchers who are involved in the study of peptide structure, neuropeptide biology and analytical characterisation can look at the available research materials.
View research materialsFAQs
References
- Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001 Apr;131(4):315-7. doi: 10.1023/a:1017979514274. PubMed ↗
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. doi: 10.2174/0929866525666180925144642. PubMed ↗
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. doi: 10.3389/fphar.2016.00031. PubMed ↗
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006 Oct 30;1117(1):54-60. doi: 10.1016/j.brainres.2006.07.108. Epub 2006 Sep 22. PubMed ↗
- Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006 Apr;97 Suppl 1:82-6. doi: 10.1111/j.1471-4159.2006.03658.x. PubMed ↗
- Agapova TIu, Agniullin IaV, Silachev DN, Shadrina MI, SlominskiÄ PA, Shram SI, Limborskaia SA, Miasoedov NF. [Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex]. Mol Gen Mikrobiol Virusol. 2008;(3):28-32. Russian. PubMed ↗
- Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001 Aug 3;308(2):115-8. doi: 10.1016/s0304-3940(01)01994-2. PubMed ↗
